Read on Twitter
Results announced by AstraZeneca today after analysing 11,636 people who received 2 regimes of vaccine.
2741 people got the 1/2 dose-full dose regimen taken 1 month apart: 90% efficacy
8895 people got the 2 full dose regimen: 62% efficacy
See
1/7 https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
2741 people got the 1/2 dose-full dose regimen taken 1 month apart: 90% efficacy
8895 people got the 2 full dose regimen: 62% efficacy
See
1/7 https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
Total cases of COVID-19:
131
Overall efficacy:
70% (for 11,636 people)
p <0.0001
Side effects:
“No hospitalisations, no severe COVID-19 cases among those who got the vaccine”
Location:
UK(12,390), Brazil (10,300)
Temperature for storage, transport: 2-8°C
Route: IM
2/8
131
Overall efficacy:
70% (for 11,636 people)
p <0.0001
Side effects:
“No hospitalisations, no severe COVID-19 cases among those who got the vaccine”
Location:
UK(12,390), Brazil (10,300)
Temperature for storage, transport: 2-8°C
Route: IM
2/8
Type of vaccine:
Viral vector vaccine
What does that mean in plain English?
Basically it is a common cold virus* that has the additional capacity to order our body to make the spike protein of the SARS-CoV2 virus.
Next: Some basic vaccine genetics explained.
3/8
Viral vector vaccine
What does that mean in plain English?
Basically it is a common cold virus* that has the additional capacity to order our body to make the spike protein of the SARS-CoV2 virus.
Next: Some basic vaccine genetics explained.
3/8
”Replication deficient recombinant chimpanzee adenovirus vector”
Means that the virus used in the vaccine is unable to cause an infection, but carries a (“cut & pasted”) foreign genetic code that tells our body to manufacture the spike protein of the SARS-CoV2 virus.
4/8
Means that the virus used in the vaccine is unable to cause an infection, but carries a (“cut & pasted”) foreign genetic code that tells our body to manufacture the spike protein of the SARS-CoV2 virus.
4/8
Once this genetically engineered adenovirus infects the human cell, it delivers this genetic code into the nucleus. The DNA in our nucleus responds to the code and starts manufacturing spike protein.
5/8
5/8
Our body then detects this spike protein and mounts an immune response, confusing it for a “real” SARS-COV-2 infection.
It is hoped that this response will protect us if and when the “real” virus attacks us. Efficacy is the % reduction in disease seen in the vaccine group.
6/8
It is hoped that this response will protect us if and when the “real” virus attacks us. Efficacy is the % reduction in disease seen in the vaccine group.
6/8
The carrier virus, being genetically engineered to be “replication deficient” (think of it like a virus who had a vasectomy) is unable to multiply in the cell, and does not cause infection. Its mission is accomplished as soon as it delivers the code into our nucleus.
7/8
7/8
In summary, the interim results of the Astra-Oxford vaccine show a 70% reduction in disease in the vaccinated group. The lower dose regimen was more effective.
The results are not peer reviewed or published yet, but an IDSM board said the vaccine met its primary endpoint.
8/8
The results are not peer reviewed or published yet, but an IDSM board said the vaccine met its primary endpoint.
8/8
